• About us
• Contact

Advertisement

Organisation › Details

Catalent (Group)

Catalent is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs. Catalent helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply over 70 billion doses of more than 7,000 products annually. Catalent’s expert workforce exceeds 18,000, including more than 2,500 scientists and technicians. Headquartered in Somerset, New Jersey, the company generated $4 billion in revenue in its 2021 fiscal year. *

 

	Start	2011-08-13 existent
	Predecessor	Cardinal Health (Group)
	Industry	drug discovery services
	Industry 2	contract manufacturing (drugs)
	Person	Chiminski, John (Catalent 201904 CEO)
	Person 2	Riley, Mike (Catalent 201805 VP + General Manager of Drug Substance + Bioanalytical Services at Catalent Biologicals)
	Region	Somerset, NJ
	Country	United States (USA)
	Street	14 Schoolhouse Road
	City	08873 Somerset, NJ
	Tel	+1-877-587-1835
		Address record changed: 2020-12-02
Basic data	Employees	H: 10,001 to 50,00 (2022-04-06)
	Currency	USD
	Annual sales	4,000,000,000 (revenue, consolidated (FY2021) 2021-12-31)
		* Document for »About Section«: Catalent, Inc.. (4/6/22). "Press Release: Catalent Acquires Facility in Oxfordshire to Expand Biologics Capabilities in the UK and Across Europe". Somers, NJ.
		Record changed: 2023-07-10

Advertisement

More documents for Catalent (Group)

• [1] Abzena Ltd.. (6/6/23). "Press Release: Abzena Appoints Thomas Castellano as Chief Financial Officer". San Diego, CA....
• [2] Catalent, Inc.. (4/6/22). "Press Release: Catalent Acquires Facility in Oxfordshire to Expand Biologics Capabilities in the UK and Across Europe". Somers, NJ....
• [3] Catalent. (6/24/21). "Press Release: Catalent to Acquire RheinCell Therapeutics, Strengthening a Path Towards Industrialization of Induced Pluripotent Stem Cell-based Therapies". Somerset, NJ....
• [4] Osborne Clarke. (2/25/21). "Press Release: Osborne Clarke Advised Delphi Genetics on Its Acquisition by Catalent"....
• [5] Catalent. (2/23/21). "Press Release: Catalent to Acquire Delphi Genetics and Launch US Plasmid Manufacturing Site to Establish Global pDNA Development and Manufacturing Capabilities". Somerset, NJ & Gosselies....
• [6] T-Knife GmbH. (9/21/20). "Press Release: T-Knife and Catalent Sign Technology Transfer and Manufacturing Agreement for Autologous T-Cell Receptor-Based Cell Therapy". Berlin & Somerset, NJ....
• [7] Imcyse S.A.. (9/7/20). "Press Release: Imcyse Announces the Appointment of Denis Bedoret as Chief Executive Officer". Liège....
• [8] Catalent, Inc.. (2/3/20). "Press Release: Catalent to Acquire Leading Cell Therapy Company MaSTherCell Global for $315 Million, Creating an Industry-Leading Cell & Gene Therapy Platform". Somers, NJ & Gosselies....
• [9] Catalent, Inc.. (2/3/20). "Press Release: Catalent, Inc. Announces Pricing of Public Offering of Common Stock". Somers, NJ....
• [10] Nanoform Finland Oyj. (1/13/20). "Press Release: Nanoform Appoints Head of US Sales". Helsinki....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2023. Made in Germany.